A Delaware judge this week ordered formal submissions from both Unilife (NSDQ:UNIS) and Insulet (NSDQ:PODD) as the companies fought over Unilife’s Chapter 11 sale, with Insulet claiming Unilife is selectively refusing to supply appropriate information and restricting it’s ability to participate. Insulet claims that Unilife has not provided it with enough data to make an informed bid […]
Blaze Bioscience touts Phase 1 data from pediatric oncology Tumor Paint BLZ-100 study
Oncology-focused biotech company Blaze Bioscience today released clinical data from the Phase 1 study of its Tumor Paint BLZ-100 in pediatric brain cancer patients, touting that the agent was well tolerated. Data from the study was presented at the 4th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in New York. The BLZ-100 is the […]
BD recalls select Plastipak catheter tip syringes over leakage issues
Becton Dickinson (NYSE: BDX) is initiating a voluntary product recall for its 100ml Plastipak catheter tip syringes over leakage issues the company caught during testing. The Franklin Lakes, N.J. company discovered that the devices, which are labeled with a 5-year expiration date, were found to be failing during routine real-time stability tests, beginning at the […]
Sanofi, Parexel collaborate on clinical trial data collection wearables
Parexel said today it is collaborating with Sanofi (NYSE:SNY) to develop and promote wearable devices to improve collection of data during clinical trials. Through the collaborative deal, the 2 companies will leverage their specific expertise to explore how wearables could improve study performance and new drug development and how sensors from several wearable devices could be […]
Ascensia Diabetes Care inks integration deal with Insulet
Ascensia Diabetes Care said today it inked a strategic alliance with Insulet (NSDQ:PODD) to integrate connectivity between Insulet’s next-gen Omnipod system with Ascensia’s Contour Next One blood glucose monitoring system. Through the deal, Parsippany, N.J.-based Ascensia’s Contour Next will be designed to pair via Bluetooth with the Omnipod Dash personal diabetes manager to automatically communicate blood glucose […]
Diabetes double play: Medtronic launches MiniMed 670G, Dexcom wins FDA nod for Android G5 app
Medtronic (NYSE:MDT) and Dexcom (NSDQ:DXCM) today announced respective wins for their diabetes care tech, with Medtronic launching its hybrid closed loop MiniMed 670G in the US and Dexcom winning an FDA nod for a Google (NSDQ:GOOG) Android G5 Mobile application. Fridley, Minn.-based Medtronic’s MiniMed 670G is designed to automatically track and adjust blood sugar levels in patients […]
Sirtex SIR-Spheres fail to improve survival in colorectal trial
Sirtex Medical (ASX:SRX) saw shares tumble more than 25% today after a trial of its radioactive microspheres reported no effect in improving survival in patients with colorectal cancer. Results from the Foxfire analysis study indicated that the use of SIR-Spheres Y-90 microspheres in combination with chemotherapy did not improve overall survival in patients with unresectable […]
Med device, drug delivery companies join J&J’s Toronto JLABS incubator
Johnson & Johnson (NYSE:JNJ) said today it has added 24 companies, including those in the medical device and drug delivery fields, to its JLABS incubator facility in Toronto, Canada. The facilities in Toronto now host over 40 companies, according to Johnson & Johnson, all of which are provided with lab space and offices, modular lab […]
Ocular Therapeutix shares fall on Q1 miss
Shares in Ocular Therapeutix (NSDQ:OCUL) fell today after the ophthalmologic device developer posted 1st quarter earnings that missed expectations on Wall Street. The Bedford, Mass.-based company posted losses of $16 million, or 58¢ per share, on sales of $475,000 for the 3 months ended March 31, seeing losses grow 47.8% while sales grew 14.2% compared with […]
Sanofi decides to keep Cepia biz
Sanofi (NYSE:SNY) has decided to keep its Cepia chemical unit, a spokesperson for the company said on Friday. The Cepia division, which deals with what Sanofi calls ‘third party activities’ such as the supply and production of active pharmaceutical ingredients, was previously being considered for sale in a deal that could have been worth up […]
